US Patent

US11679210 — Dispensing device and pharmaceutical composition for the treatment of rhinitis

Formulation · Assigned to Glenmark Specialty SA · Expires 2038-09-03 · 12y remaining

Vulnerability score 33/100 Strong — defensible against typical IPR challenges

What this patent protects

This patent protects a nasal dispensing device and a pharmaceutical composition containing mometasone and olopatadine for treating rhinitis.

USPTO Abstract

A nasal dispensing device and pharmaceutical composition includes a container; a dispenser head having at least a pump, a dispensing channel, and a dispensing orifice; a dip tube; and a pharmaceutical composition comprising mometasone, an ester thereof (e.g., mometasone furoate), or a salt thereof and olopatadine or its salt (e.g., olopatadine hydrochloride). The container can have a conically shaped internal bottom, angled downwardly toward a center, and a further angularly deepened well, centrally located, with the dip tube extending into the well. An optional cap is provided that includes a sealing sleeve communicating in a seal tight manner with a perimeter of a lateral wall of the dispenser head.

Drugs covered by this patent

Patent Metadata

Patent number
US11679210
Jurisdiction
US
Classification
Formulation
Expires
2038-09-03
Drug substance claim
No
Drug product claim
Yes
Assignee
Glenmark Specialty SA
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.